Tonix Pharmaceuticals stock halted ahead of FDA approval news
LONDON - UBS Group AG (NYSE:UBS) has disclosed the possibility of market stabilization activities in connection with a new securities offering, beginning today, as per a notice from the investment bank’s debt syndicate team. The securities in question are described as 4NC3 FRN Senior HoldCo with an aggregate nominal amount set at a benchmark level in euros. The offer price and other terms are yet to be confirmed.
Stabilization efforts, if undertaken by UBS AG London Branch, the named Stabilising Manager, are expected to commence today and could continue until no later than June 10, 2025. The bank may engage in over-allotment or other transactions to support the market price of the securities at a higher level than might naturally occur. However, there is no guarantee that stabilization will occur, and if initiated, it can cease at any time.
The stabilization mechanism is a strategy permitted under Commission Regulation (EC) No. 2273/2003, which is part of the Market Abuse Directive. It allows the Stabilising Manager to over-allot securities or conduct transactions to maintain the market price.
This announcement serves as a clarification for investors and market participants, indicating that the stabilization action is purely discretionary and not a definitive plan. It is also a reminder that the offer is not an invitation to the general public but is targeted at qualified investors or those with professional investment experience in the UK, as well as those in the EEA who fall under the "qualified investors" category as defined by the Prospectus Directive.
The securities mentioned are not available for sale in the United States and have not been registered under the United States Securities Act of 1933. Consequently, they may not be offered or sold within the United States without registration or an applicable exemption from such registration requirements.
This information is based on a press release statement and is intended for informational purposes only, providing essential details to investors without any endorsement of the claims.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.